European Archives - Page 66 of 1138 - European Medical Journal

Maternal Flu Vaccination: Reducing Risks for Newborns

Beyond antibody transfer through the placenta, breastfeeding may further enhance infant protection.

Gene Therapy Shows Promise for Liver Disease Treatment

A recent first-in-human gene therapy trial using DTX401 has shown promising results in improving glucose homeostasis.

Neuroimaging Reveals Donanemab Treatment Increases ARIA Risk in Alzheimer’s Disease

Donanemab raises ARIA risk in Alzheimer’s, requiring vigilant monitoring.

One-Third of Women With Lupus Suffer From Depression

A new study reveals high rates of depression and fibromyalgia in Jordanian women with lupus, calling for an integrated approach to managing both physical and psychological aspects of the disease.

Depression Tied to Higher Metabolic Risk in Women With PCOS

A new long-term study finds that women with PCOS and a history of depression or anxiety are at greater risk of developing metabolic syndrome, underscoring the need for integrated mental and metabolic health care.

Immunotherapy Boosts Chemotherapy Efficacy in Early-Stage Breast Cancer

Nivolumab enhances chemotherapy efficacy in high-risk ER+/HER2− breast cancer, offering new treatment potential for early-stage patients.

Sanofi's chlamydia vaccine fast-tracked by FDA

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Childhood Tuberculosis on the Rise in Europe: Call to Action

The ECDC reports an alarming 10% rise in childhood tuberculosis cases across Europe, stressing the urgent need for enhanced prevention, diagnosis, and treatment.

Higher Calcium Intake Linked to Reduced Colorectal Cancer Risk

New findings from a decades-long study of over 470,000 adults show that higher calcium intake may significantly reduce the risk of colorectal cancer, regardless of whether it comes from dairy, non-dairy foods, or supplements.

Spesolimab: A Breakthrough in Treating Generalised Pustular Psoriasis

Spesolimab, a monoclonal antibody targeting the interleukin (IL)-36 receptor, has been approved as the first GPP-specific therapy.